Clearasil sales
This article was originally published in The Rose Sheet
Executive Summary
"Good progress" has been made on the integration and rejuvenation of the acne treatment brand, which contributed over $114.5 mil. (£1=$1.46) in sales worldwide in its first full year, Boots says in its fiscal 2002 financial review May 30. Operating profits for the brand rose by over 13% to $97.9 mil. for the year ended March 31 and the total investment in Clearasil reached $165.8 mil., retailer adds. In the U.S., retail sales for Clearasil were up 1% to $34.4 mil. in the 52 weeks ended April 21, according to Information Resources, Inc. data for food, drug and mass outlets, excluding Wal-Mart...
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.